Fact-checked by Grok 2 weeks ago

Isosorbide


Isosorbide is a bicyclic with the molecular formula C₆H₁₀O₄, consisting of two fused rings formed as an derivative of D-glucitol ().
It is produced industrially through the acid-catalyzed double dehydration of , which itself is derived from the of glucose sourced from or .
As a versatile bio-based chemical, isosorbide serves primarily as a precursor for organic nitrate esters, including isosorbide dinitrate and isosorbide mononitrate, which are used to prevent and treat angina pectoris in by promoting .
These nitrates function via biotransformation to , which stimulates in vascular smooth muscle, elevating levels to induce relaxation and reduce cardiac preload and .
Isosorbide mononitrate, the of dinitrate, exhibits higher and a longer elimination (approximately 5 hours versus 1 hour for dinitrate), enabling simpler once-daily dosing regimens.
Beyond pharmaceuticals, isosorbide is employed as a renewable in the production of polyesters, polycarbonates, and other eco-friendly polymers, leveraging its rigidity and for enhanced material properties.

History

Discovery and Early Synthesis

Isosorbide, or 1,4:3,6-dianhydro-D-glucitol, was first synthesized in 1948 by W. N. and L. F. Wiggins via acid-catalyzed double of . serves as the starting material, obtained through catalytic of D-glucose, which itself derives from the of . This process involves sequential steps, first forming a intermediate (1,4-anhydrosorbitol) followed by a second cyclization to the bicyclic . Early structural insights emerged from the 1940 synthesis and analysis of , the 2,5-dinitrate ester of the , reported by researchers at the University of Maryland. This derivative's preparation from sorbitol anhydrides highlighted the fused bicyclic framework, consisting of two rings linked by an oxygen bridge, confirmed through chemical derivatization and solubility properties. The precise bicyclic structure underwent empirical verification in the post-1950s era using advancing spectroscopic techniques, including for identification and emerging for ring confirmation, building on initial degradative and synthetic proofs. These methods corroborated the endo-exo orientation of the hydroxyl groups and the overall rigidity of the molecule derived from first-principles mechanisms of the linear chain.

Development of Pharmaceutical Derivatives

In the 1950s, was independently synthesized by Harris and colleagues, marking a key advancement in derivatives for therapeutic applications. Early pharmacological evaluations demonstrated its vasodilatory potency, with hemodynamic effects persisting for at least one hour, exceeding the duration observed with in comparative studies. These findings highlighted 's potential for sustained action relative to other organic s, prompting further exploration despite challenges like rapid tolerance development noted in initial trials. Isosorbide itself emerged as an oral in the mid-1960s, with preclinical studies confirming its efficacy in promoting through hyperosmotic mechanisms without significant gastrointestinal irritation or at therapeutic doses. By the 1970s, gained traction as an anti-anginal agent, with clinical investigations establishing its role in relieving exertional via coronary , though adoption remained tempered by evidence of attenuated responses during prolonged administration. The saw broader recognition of isosorbide nitrates in managing ischemic heart disease, including the development of isosorbide-5-mononitrate as a designed to leverage its status as the primary of dinitrate, aiming to reduce through once-daily dosing. Initial limited uptake stemmed from pharmacokinetic data revealing rapid onset of , necessitating intermittent dosing strategies in early protocols. Commercial production advancements, such as ' initiation of pharmaceutical-grade isosorbide synthesis in a pilot unit, supported for medical applications.

Chemistry

Molecular Structure and Isomers

Isosorbide is a bicyclic with the systematic name (3R,3aR,6S,6aR)-hexahydrofuro[3,2-b]furan-3,6-diol, corresponding to a 1,4:3,6-dianhydro-D-glucitol core. This structure comprises two fused rings formed by intramolecular of D-glucitol (), eliminating water molecules between the 1- and 4- hydroxyl groups and the 3- and 6- hydroxyl groups, respectively. The resulting framework positions two vicinal hydroxyl groups at carbons 2 and 5, one in an orientation and the other relative to the bicyclic system, conferring a rigid, V-shaped conformation absent in the flexible, acyclic parent hexitol. As one of the isohexide stereoisomers, isosorbide exhibits distinct compared to isomannide (1,4:3,6-dianhydro-D-mannitol, with both hydroxyls ) and isoidide (1,4:3,6-dianhydro-L-iditol, with both exo). Derived specifically from D-glucitol, isosorbide's endo-exo configuration at the 2- and 5-positions introduces four chiral centers, enabling inherent that influences molecular reactivity and packing, unlike the achiral or differently oriented isomers. The molecular structure has been rigorously confirmed through , revealing the precise fused-ring geometry and stereocenters, and NMR spectroscopy, which verifies proton and carbon environments consistent with the bicyclic rigidity. These techniques underscore the absence of conformational flexibility seen in acyclic polyols, attributing stability to the bridges.

Physical and Chemical Properties

Isosorbide appears as a white to off-white crystalline solid that is hygroscopic and stable under inert atmosphere at room temperature. Its melting point ranges from 60 to 63 °C. The boiling point is 175 °C at 2 mmHg pressure, reflecting low volatility with a vapor pressure of 0.007 Pa at 20 °C. Density is estimated at approximately 1.1 g/cm³. It exhibits high water solubility exceeding 200 g/L at 20 °C and is also soluble in alcohols and ketones. The specific optical rotation is +42° (c=3 in water), consistent with its chiral structure derived from D-sorbitol.
PropertyValue
Melting point60–63 °C
Boiling point175 °C (2 mmHg)
Density~1.1 g/cm³
Water solubility>200 g/L (20 °C)
Vapor pressure0.007 Pa (20 °C)
Optical rotation[+42°] (c=3, H₂O)
As a bicyclic with two secondary hydroxyl groups in a configuration, isosorbide displays reactivity typical of vicinal diols, readily undergoing esterification, etherification, and nitration at the hydroxyl sites to form derivatives like mononitrates and dinitrates. The fused rings, featuring linkages, impart hydrolytic stability under neutral or basic conditions due to , though acidic conditions can promote ring opening. The values for the hydroxyl groups are predicted at approximately 13.2, indicating weak acidity comparable to other secondary alcohols. Infrared spectroscopy reveals characteristic broad O-H stretching bands at 3200–3600 cm⁻¹ due to hydrogen bonding, alongside C-O stretches around 1000–1200 cm⁻¹ from the ether linkages. Proton NMR spectroscopy shows distinct signals for the anomeric protons (at the ring oxygen-bearing carbons) in the 4.5–5.0 ppm range, with methylene and methine protons appearing upfield, facilitating structural confirmation in complex mixtures. These signatures enable reliable identification and purity assessment via standard analytical techniques.

Production

Synthesis from Renewable Sources

Isosorbide is primarily synthesized through the acid-catalyzed double dehydration of D-sorbitol, a derived from renewable biomass feedstocks such as or lignocellulosic materials. D-Sorbitol is obtained via of D-glucose, which itself results from the enzymatic or acid of or the of in . This pathway leverages abundant renewable carbohydrates, with sorbitol serving as a key intermediate due to its high availability from industrial glucose processing. The dehydration process proceeds in two sequential steps under acidic conditions: first, intramolecular dehydration of D-sorbitol to 1,4- (also known as sorbitan), followed by a second dehydration to form the bicyclic isosorbide structure. Traditional catalysts include , achieving yields up to 72% isosorbide after 180 minutes at elevated temperatures, though optimized conditions with solid acids like resins or zeolites can reach 80-88% yield while minimizing byproducts such as through controlled and temperature to favor endo-cyclic dehydration over epimerization. Recent heterogeneous catalysts, such as sulfated zirconia, enhance selectivity to 74-82% isosorbide at 220-473 , verified by gas chromatography-mass spectrometry (GC-MS) with purities exceeding 99% for the target product. Alternative routes from bypass direct glucose isolation by integrating production via catalytic or enzymatic . In 2020s developments, bifunctional magnetic Ru-enzyme catalysts enable sustainable one-pot conversion of cellulose derivatives to D- with improved selectivity over traditional chemocatalytic methods, setting the stage for subsequent to isosorbide while reducing energy inputs and waste. These enzymatic advancements address limitations in stereo-selectivity during , yielding intermediates suitable for high-purity isosorbide without significant contamination. Empirical data confirm overall process efficiencies approaching 80% from cellulose-derived under mild conditions, prioritizing causal pathways that align kinetics with biomass-derived precursor stability.

Industrial Manufacturing Processes

Industrial production of isosorbide primarily involves the acid-catalyzed double dehydration of , derived from glucose, in continuous-flow reactors to enhance , yield consistency, and waste minimization. Heterogeneous catalysts, such as zeolites (e.g., H-β with Si/Al ratio of 38), replace traditional homogeneous mineral acids like , enabling efficient liquid-phase operation under hydrothermal conditions while facilitating catalyst reuse and reducing effluent generation. These processes typically operate at temperatures of 200–250°C and pressures sufficient to maintain liquid phase, with continuous water removal via or separation to drive toward the bicyclic product. Leading producer operates the world's largest dedicated isosorbide facility in Lestrem, , commissioned in 2007 with initial capacity in the thousands of tons per year, expanded in 2011 and 2015 to 20,000 metric tons annually. The plant achieves pharmaceutical-grade purity (>99.5%) through integrated purification steps including and , supporting both active pharmaceutical ingredient () intermediates and polymer monomer applications. Continuous plug-flow reactor designs at such scales yield 70–85% isosorbide from feedstock, with sorbitol conversion exceeding 95%, though side products like require separation. Process metrics emphasize cost-effectiveness: energy inputs are optimized via heat integration in and , with overall yields translating to approximately 0.7–0.8 kg isosorbide per kg input after accounting for purification losses. The bio-based pathway yields a low of 0.09 kg CO₂ equivalent per kg product, significantly below petroleum-derived analogs (often >2 kg CO₂/kg), due to renewable sourcing and minimal fossil inputs. Recent advancements in catalyst stability extend operational cycles beyond 1,000 hours, further improving reproducibility for large-scale output.

Pharmaceutical Applications

Nitrates for Cardiovascular Treatment

Isosorbide dinitrate (ISDN) and isosorbide-5-mononitrate (ISMN) serve as prodrugs that release , which activates in vascular cells, elevating levels to induce relaxation and of both venous and arterial beds. This reduces cardiac preload via venous capacitance increase and via arterial dilation, thereby lowering myocardial oxygen demand without substantially elevating heart rate or contractility in prophylactic regimens. Both compounds received FDA approval for the prevention of angina pectoris due to , with ISDN indications established by the mid-1970s based on controlled trials demonstrating reductions in exercise-induced ischemia. Typical oral dosing for ISDN involves 5-40 mg administered two to three times daily, while sustained-release formulations (e.g., 40 mg capsules) extend anti-ischemic effects for approximately 12 hours when taken once or twice daily; ISMN dosing starts at 20 mg twice daily, with the second dose delayed 7 hours to minimize peak-trough fluctuations. Clinical trials from the 1960s through 1980s, including those published in Circulation, reported empirical reductions in weekly episodes with oral ISDN therapy versus , alongside improved exercise tolerance in stable patients, though effects waned beyond 6-8 hours without dosing adjustments. Meta-analyses of class agents, encompassing isosorbide derivatives, confirm prophylaxis benefits in decreasing attack frequency and consumption, albeit with variable quality-of-life impacts. Tolerance to isosorbide nitrates develops rapidly with continuous exposure, manifesting as attenuated hemodynamic responses (e.g., diminished reductions in pulmonary wedge and systemic ) within hours to days, necessitating intermittent nitrate-free periods (typically 10-12 hours daily) to restore sensitivity. Studies using invasive monitoring during ISDN infusion or oral regimens demonstrate this extends to other nitrates, attributable to mechanisms including and neurohormonal counter-regulation rather than depleted .

Other Derivatives and Emerging Uses

Isosorbide itself functions as an oral , drawing fluid from tissues into the bloodstream to reduce intracranial and in conditions such as and acute . Historical studies in the demonstrated its efficacy when administered at initial doses of 1.5 g per kg body weight, with onset of typically within 30 minutes and peak effects lasting several hours, attributed to its hygroscopic properties and rapid absorption without gastrointestinal irritation. Its low acute and subacute toxicity supported experimental use in lowering pressure and brain mass in animal models, though it has largely been supplanted by other agents like . Ethers of isosorbide, such as dimethyl isosorbide (DMI), enhance the of poorly water-soluble active pharmaceutical ingredients in topical and formulations. DMI acts as a , increasing by up to several-fold in aqueous systems, and exhibits hydrotropic effects that improve without significant at concentrations around 10%. These properties position DMI as a vehicle in systems, where it facilitates the formulation of APIs requiring better , though its enhancement of dermal varies by compound and is not universally potent. Incorporation of isosorbide-derived isohexide subunits into bioactive molecules has shown potential to boost overall drug-like properties, including permeability and metabolic stability, in preclinical designs. Emerging applications include topical isosorbide mononitrate gels for chronic anal fissures, evaluated in phase I trials like NCT02667535 for , , and safety in healthy participants and patients. These formulations leverage localized to promote healing, with trial data indicating comparable profiles to but reduced systemic exposure. However, the short plasma of isosorbide derivatives, approximately 4-5 hours for mononitrate forms, limits their utility in prolonged acute interventions, as confirmed in recent assessments emphasizing rapid clearance and the need for repeated dosing.

Pharmacokinetics, Mechanism, and Efficacy Evidence

Isosorbide dinitrate exhibits rapid oral absorption, with peak plasma concentrations (Tmax) typically reached within 1 to 2 hours, though bioavailability is reduced to approximately 20-25% due to extensive first-pass hepatic metabolism. It is primarily denitrated in the liver to active metabolites isosorbide-2-mononitrate and isosorbide-5-mononitrate, which undergo further glucuronidation to inactive forms before renal excretion. The elimination half-life of the parent compound is short, around 30 minutes, while isosorbide-5-mononitrate persists longer at 4-5 hours, contributing to sustained effects in extended-release formulations. In contrast, isosorbide-5-mononitrate demonstrates near-complete bioavailability (>90%) with minimal first-pass metabolism, achieving Tmax of 1-2 hours and hepatic clearance to renally excreted conjugates. A 2025 bioequivalence study in Chinese healthy volunteers confirmed comparable area under the curve and maximum concentrations for generic sustained-release isosorbide mononitrate tablets versus the reference under both fasting and fed states, supporting pharmacokinetic consistency across populations. The pharmacological mechanism of isosorbide nitrates relies on enzymatic denitration to release (NO), which diffuses into vascular cells to stimulate soluble , elevating (cGMP) and promoting dephosphorylation of myosin light chains for relaxation. This induces preferential venodilation, reducing preload and myocardial oxygen demand, with lesser arterial effects on . Endogenous counter-regulatory responses, including neurohormonal activation and volume expansion, contribute to rapid development, with empirical data showing >50% attenuation of vasodilatory and anti-ischemic effects after 24-48 hours of continuous exposure due to mechanisms like sulfhydryl depletion, generation, and mitochondrial aldehyde dehydrogenase-2 inhibition. Eccentric dosing regimens mitigate but do not eliminate this . Efficacy evidence from randomized controlled trials supports isosorbide nitrates for prophylaxis in chronic stable , where meta-analyses of short- and long-term studies report significant reductions in attack frequency (typically 50-70%) and improved exercise duration to ischemia onset via preload reduction. However, a 2015 multicenter double-blind RCT (n=110) in with preserved (HFpEF) found isosorbide mononitrate (up to 120 mg daily) conferred no benefits in daily activity, , or exercise capacity over , instead associating with reduced and higher discontinuation rates due to symptoms. In acute , trials indicate no mortality or infarct size reduction in non-selected patients, with guidelines contraindicating routine use owing to hemodynamic risks and lack of causal benefit.

Industrial Applications

Use as a Monomer in Polymers

Isosorbide serves as a rigid, bio-based in the of polycarbonates and polyesters, offering a renewable alternative to petroleum-derived components like . Its bicyclic structure imparts enhanced thermal stability and mechanical properties to the resulting polymers, with isosorbide-based polycarbonates achieving temperatures (Tg) above 140°C, enabling applications requiring heat resistance such as optical lenses and electronic components. These polymers also demonstrate improved optical clarity and tensile strength compared to traditional counterparts, as noted in reviews of bio-based polymer advancements. Polymerization typically proceeds via of isosorbide with or diacid methyl esters, catalyzed by organobases like 1,5,7-triazabicyclo[4.4.0]dec-5-ene (), yielding high-molecular-weight materials exceeding 50 kDa. For instance, melt under optimized conditions produces polycarbonates with weight-average molecular weights around 53,200 g/mol and polydispersity indices near 2.0, facilitating scalable industrial production. Certain isosorbide-modified poly(ethylene terephthalate) () copolymers have received authorization for food-contact applications under Regulation (EU) No 10/2011, complying with overall migration limits below 10 mg/dm² through rigorous simulant testing. Empirical sustainability metrics highlight isosorbide polymers' environmental benefits, including biodegradability rates reaching 60-70% mineralized carbon in 28 days under 301B conditions for select copolyesters, surpassing many conventional plastics. Their production from renewable feedstocks results in a approximately 50-70% lower than phthalate-plasticized or A-based equivalents, driven by biogenic and reduced fossil input. These attributes position isosorbide-derived polymers as viable for rigid and durable goods, though challenges in achieving uniform high molecular weights without side reactions persist.

Solvents, Additives, and Other Non-Pharmaceutical Roles

Isosorbide functions as a bio-based in chemical processes, leveraging its renewable origin from and properties such as a around 225°C at and compatibility with polar organics for extractions and . Its low and eco-friendly profile position it as an alternative to petroleum-derived s like NMP or DMF in applications requiring high solvency for lignocellulosic materials, though derivatives like dimethyl isosorbide are more commonly employed for membrane preparation and polymer processing due to enhanced miscibility. In 2025, adoption trends reflect broader demands, with isosorbide's roles contributing to the compound's market growth amid rising interest in bio-based alternatives for and pretreatment. As an additive, isosorbide acts as a in coatings and adhesives, improving flexibility and in and PVC formulations without inducing retrogradation or . In coatings, it serves as a plant-based feedstock that reduces environmental impact while enhancing performance over substitutes, particularly in high-performance polymers. For adhesives, epoxidized isosorbide esters provide secondary plasticizing effects with long alkyl chains, supporting eco-friendly waterborne systems and in sensitive applications. Projections for 2025 indicate expanding use in biodegradable plastics and , aligning with a market CAGR of approximately 8% driven by regulatory pushes for non-phthalate additives. Toxicity data supports its suitability for non-pharmaceutical roles, with an oral LD50 in rats reported at 2010 mg/kg, indicating low acute and enabling applications in and contact materials pending regulatory approval. These attributes, combined with its non-migratory behavior in plasticized systems, underscore isosorbide's value in functions distinct from its polymeric applications.

Safety and Toxicology

Adverse Effects and Clinical Risks

Common adverse effects of and mononitrate, used primarily as organic nitrates for and , include dose-related manifesting as , , and reflex . occurs in greater than 10% of patients, often resolving with continued use or mitigated by dose adjustment, while orthostatic and reflex affect 0.1-10% and are linked to venous and arterial dilation. These effects stem from nitric oxide-mediated relaxation, with incidence decreasing over time due to but potentially exacerbated by rapid . Nitrate tolerance develops through vascular desensitization and , reducing efficacy with continuous exposure; clinical strategies include nitrate-free intervals (e.g., 10-12 hours daily) to restore responsiveness, as continuous dosing impairs activity and biotransformation. Severe risks are infrequent but include , occurring rarely (<1% at therapeutic doses) via oxidation, typically reversible with discontinuation and if symptomatic. Profound arises from interactions with phosphodiesterase-5 (PDE5) inhibitors like , contraindicated due to synergistic cGMP elevation causing ; coadministration is avoided, with nitrates withheld for at least 24-48 hours post-PDE5 use depending on the agent. Contraindications encompass severe , , and caution in due to potential elevation, alongside risks in or autonomic dysfunction amplifying orthostasis. In heart failure with preserved (HFpEF), the 2015 NEAT-HFpEF trial found well-tolerated pharmacokinetically but associated with reduced daily activity levels (dose-dependent decline vs. ) and no gains in exercise capacity or , highlighting limited utility and potential for functional detriment in this population. Recent pharmacokinetic trials (2020-2025) confirm overall tolerability in studies, with adverse events primarily mild effects and no new safety signals at standard doses.

Environmental Impact and Biodegradability

Isosorbide, derived from renewable biomass sources such as , exhibits low environmental persistence due to its bio-based structure and susceptibility to microbial degradation. Studies indicate that isosorbide itself is readily biodegradable, preventing in ecosystems, which positions it as an eco-friendlier alternative to petroleum-derived compounds in industrial applications. In environments, isosorbide demonstrates accelerated upon microbial adaptation, with rates increasing from 0.5 mg CO₂ per day to 2.4 mg CO₂ per day within four days in pre-exposed conditions, as observed in experiments with poly(isosorbide-co-1,6-hexanediol) copolymers. Higher isosorbide content in such copolyesters correlates with enhanced extents, reaching up to 97.2% after eight weeks in burial tests for formulations with 30 mol% isosorbide. degradation is slower but significant, achieving 68.3% over 32 weeks under similar compositions. These findings underscore isosorbide's role in promoting hydrolytic and enzymatic breakdown in polyesters, reducing plastic persistence compared to non-bio-based analogs. Ecotoxicity data for isosorbide monomers vary by derivative: acrylate forms show toxicity to aquatic higher organisms (e.g., EC₅₀ values indicating moderate hazard) and bacteria, while methacrylate variants are generally harmless, with polymers exhibiting reduced bioavailability and lower risks. For pharmaceutical derivatives like isosorbide-5-mononitrate, ecotoxicity testing is limited, but predicted environmental concentrations yield a PEC/PNEC ratio of 1.86 × 10⁻⁴, suggesting negligible risk from therapeutic use. No widespread evidence of significant adverse ecosystem effects from isosorbide production or disposal exists, though gaps in biodegradation data for nitrated forms warrant further monitoring in wastewater contexts.

References

  1. [1]
    Isosorbide | C6H10O4 | CID 12597 - PubChem - NIH
    Isosorbide is an organic nitrate with vasodilator activity. Isosorbide relaxes vascular smooth muscle by formation of the free radical nitric oxide (NO).
  2. [2]
    Continuous-Flow Production of Isosorbide from Aqueous-Cellulosic ...
    Dec 31, 2020 · In this study, a method for isosorbide synthesis from sorbitol was proposed by dehydration under high temp. and high pressure reaction.
  3. [3]
    Developing a Continuous Process for Isosorbide Production from ...
    Sep 29, 2020 · Isosorbide is produced continuously by dehydrating sorbitol using H-β (38) zeolite in a liquid-phase reactor, achieving 9670 g/kg catalyst ...
  4. [4]
    Isosorbide - StatPearls - NCBI Bookshelf - NIH
    May 16, 2023 · Isosorbide is a medication used to treat and prevent angina pectoris in patients with coronary heart disease. It is in the nitrate class of drugs.Missing: chemical | Show results with:chemical<|separator|>
  5. [5]
    Isosorbide: Uses, Interactions, Mechanism of Action | DrugBank Online
    Nov 30, 2015 · Isosorbide is a vasodilator used for the prevention and treatment of angina pectoris due to coronary artery disease. It was previously used ...Missing: definition | Show results with:definition
  6. [6]
    Isosorbide dinitrate: Uses, Interactions, Mechanism of Action
    Isosorbide Dinitrate is a moderate to long acting oral organic nitrate used for the relief and prophylactic management of angina pectoris. It relaxes the ...
  7. [7]
    Isosorbide Mononitrate Versus Dinitrate - RK.MD
    May 30, 2024 · As far as differences, ISDN has a faster onset of action (within 30 minutes), shorter duration (around 2-4 hours), requires more frequent ...
  8. [8]
    Isosorbide, a versatile green chemical: Elucidating its ADME ...
    Mar 1, 2024 · Accordingly, isosorbide is extensively used as a renewable and eco-friendly substance in various fields including polymers, functional materials ...
  9. [9]
    A Study of Isosorbide Synthesis from Sorbitol for Material ... - MDPI
    Sep 4, 2023 · The synthesis of isosorbide dimethacrylate involved a reaction with methacrylic anhydride (MAA) (catalysis of potassium acetate) and the ...
  10. [10]
    Isosorbide - American Chemical Society
    Nov 22, 2010 · Isosorbide is a sugar dehydration product. It was first prepared by WN Haworth and LF Wiggins in 1948 by dehydrating D-sorbitol, which is obtained by reducing ...
  11. [11]
    Isosorbide 652-67-5 wiki - Guidechem
    PREPARED BY ACID DEHYDRATION OF D-GLUCITOL: HAWORTH, WIGGINS, BRITISH PATENT 600,870 (1948). PURIFICATION: HARTMANN, US PATENT 3,160,641 (1964 TO ATLAS CHEM ...
  12. [12]
    History of the Synthesis and Pharmacology of Isosorbide Dinitrate
    The 1,4:3,6-dianhydrosorbitol 2,5-dinitrate (isosorbide dinitrate) was synthesized, studied, and reported in 1940. It appeared to be a useful drug.
  13. [13]
    Synthesis of isosorbide: an overview of challenging reactions
    Isosorbide is a diol derived from sorbitol and obtained through dehydration reactions that has raised much interest in the literature over the past few decades.
  14. [14]
    Historical aspects of nitrate therapy - PubMed
    The drug was first marketed in Sweden in 1946. Isosorbide dinitrate was independently synthesised in the United States by Harris and colleagues in the 1950s.
  15. [15]
    The long-acting hemodynamic effects of isosorbide dinitrate
    This study shows that isosorbide dinitrate evokes a significant hemodynamic action lasting for at least 1 hour; this effect is more prolonged than that produced ...
  16. [16]
    Tolerance to isosorbide dinitrate: rate of development and reversal.
    The present investigation was designed to determine the rate of development of tolerance during initiation of therapy with oral ISDN and the rate of tolerance.
  17. [17]
    Isosorbide, a New Oral Osmotic Diuretic - Sage Journals
    Because of its effectiveness and very low order of acute and sub-acute toxicity, isosorbide is considered as an orally effective osmotic diuretic.
  18. [18]
    Sustained hemodynamic and antianginal effect of high dose oral ...
    Twenty-one patients with documented coronary atherosclerotic heart disease were studied to determine the effect of high dose oral isosorbide dinitrate ...
  19. [19]
    Roquette brings world's largest isosorbide production unit on stream
    Apr 10, 2015 · The group launched its first pilot unit in 2002 and completed its first industrial-scale unit in 2007. Roquette almost immediately decided ...Missing: commercial | Show results with:commercial
  20. [20]
    Isosorbide: Recent advances in catalytic production - ScienceDirect
    Isosorbide is produced via two-step dehydrocyclization of sorbitol, using homogeneous acid, ionic liquids, or solid acid catalysts, and direct glucose ...
  21. [21]
    1,4:3,6-dianhydro-D-glucitol; "Isosorbide". - ResearchGate
    Isosorbide (1,4:3,6-dianhydro-D-glucitol) is a V-shaped molecule consisting of two fused tetrahydrofuran rings having two hydroxyl groups with endo and exo ...Missing: dianhydrohexitol | Show results with:dianhydrohexitol
  22. [22]
    Effects of Isohexide Stereochemistry on Vinylogous Urethane ...
    Sep 29, 2025 · Isosorbide, being one of the isohexide isomers and a biobased platform chemical originating from starch, is of large interest as a ...
  23. [23]
    Ultra‐Tough Elastomers from Stereochemistry‐Directed Hydrogen ...
    Feb 15, 2022 · The stereochemical configurations of the rigid-ring structures of isosorbide (ISPU) and isomannide (IMPU) direct strong hydrogen-bonding ...
  24. [24]
    The Stereochemistry of 1,4: 3,6-Dianhydrohexitol Derivatives1
    The synthesis and structure of gemini QASs of 1,4:3,6-dianhydro-l-iditol. Journal of Molecular Structure 2015, 1101 , 228-235. https://doi.org/10.1016/j ...
  25. [25]
    Polymers from renewable 1,4:3,6-dianhydrohexitols (isosorbide ...
    1,4:3,6-dianhydrohexitols are derived from renewable resources from cereal-based polysaccharides. In the field of polymeric materials, these diols are ...
  26. [26]
    Isosorbide | 652-67-5 - ChemicalBook
    Isosorbide ; Molecular Formula: C6H10O4 ; Molecular Weight: 146.14 ; MDL Number: MFCD00064827 ; MOL File: 652-67-5.mol ; MSDS File: SDS.
  27. [27]
    Isosorbide | CAS#:652-67-5 | Chemsrc
    Aug 21, 2025 · Chemical & Physical Properties. Density, 1.5±0.1 g/cm3. Boiling Point, 372.1±42.0 °C at 760 mmHg. Melting Point, 60-63 °C(lit.) Molecular ...Missing: solubility | Show results with:solubility
  28. [28]
    Isosorbide CAS#: 652-67-5 - ChemicalBook
    Melting point, 60-63 °C (lit.) Boiling point, 175°C/2mmHg(lit.) alpha, 42 º (c=3, H2O). Density, 1.0945 (rough estimate). vapor pressure, 0.007Pa at 20℃.Missing: physical | Show results with:physical
  29. [29]
  30. [30]
    Sustainable Sorbitol Dehydration to Isosorbide using Solid Acid ...
    ... dehydration of sorbitol to isosorbide (see Table 3). In vapor‐phase reaction, Cu2O(SO4) catalyst exhibited the highest isosorbide yield of 68 % at 473 K.
  31. [31]
    Developing a Continuous Process for Isosorbide Production from ...
    Nov 6, 2020 · Increasing demand for isosorbide has led to the search for sustainable and efficient methods for its production from sorbitol, a biomass‐derived ...
  32. [32]
    Sorbitol dehydration into isosorbide in a molten salt hydrate medium
    Mar 6, 2013 · At the optimal temperature range, without using any co-catalysts, full conversion is achieved, and the isosorbide percent yield is above 85% on ...
  33. [33]
    Sulfuric Acid-Catalyzed Dehydration of Sorbitol: Mechanistic Study ...
    Thereafter, the yield of isosorbide increased at an accelerated pace to reach 72% in 180 min. Since the conversion rate of 1,4-sorbitan to isosorbide increased ...
  34. [34]
    SOLVENT-FREE DEHYDRATION OF SORBITOL TO ISOSORBIDE ...
    Oct 27, 2021 · It was found that the studied catalysts provide 78‐88 % isosorbide yield with a complete conversion of sorbitol at 140 о C for 3 h.<|separator|>
  35. [35]
    Markedly Improved Catalytic Dehydration of Sorbitol to Isosorbide by ...
    With the optimal SZ catalyst, complete conversion of sorbitol occurred in <2 h under mild conditions to give isosorbide in 76% yield.
  36. [36]
    Magnetic Bifunctional Ru-Enzyme Catalyst Allows for Sustainable ...
    May 15, 2025 · Magnetic bifunctional Ru-enzyme catalyst allows for sustainable conversion of cellulose derivative to D-sorbitol.
  37. [37]
    Chemocatalytic production of sorbitol from cellulose via sustainable ...
    Sorbitol is produced from cellulose using chemocatalytic methods, including multi-step, one-pot, or flow-chemistry approaches with supported metal catalysts.
  38. [38]
    Developing a Continuous Process for Isosorbide Production from ...
    Sep 29, 2020 · Sorbitol dehydration to isosorbide is efficiently performed in a continuous, liquid-phase plug flow reactor, utilising an acidic zeolite (H-β (38)) as solid ...
  39. [39]
    Roquette Commissions Isosorbide Plant - CHEManager Online
    Apr 10, 2015 · Roquette said the facility in Lestrem, Pas-de-Calais, is the world's largest isosorbide production unit with a capacity of 20,000 t/y. The ...
  40. [40]
    Innovate from nature with POLYSORB® – the high purity isosorbide
    Roquette first extended our plant in 2011 and again in 2015 to become the world's largest isosorbide plant. This versatile ingredient differentiates itself ...
  41. [41]
    High yield of isosorbide production from sorbitol dehydration ...
    May 15, 2020 · The continuous water removal system accelerated the attainment of ~100% isosorbide yield within 4 h. The sorbitol dehydration was well ...
  42. [42]
    INTRODUCING ISOSORBIDE: A SUSTAINABLE, SAFE, HIGH ...
    Feb 17, 2021 · As a sustainable plant-based feedstock with a carbon footprint of just 0.09 kg CO2/kg of product, isosorbide is an attractive substitute for ...Missing: bio- | Show results with:bio-
  43. [43]
    Dilatrate-SR, Isordil (isosorbide dinitrate) dosing, indications ...
    Vasodilating agent (nitric oxide donor); relaxes smooth muscle via dose-dependent dilation of arterial and venous beds to reduce both preload and afterload.
  44. [44]
    What is the mechanism of Isosorbide Mononitrate? - Patsnap Synapse
    Jul 17, 2024 · The primary mechanism of action of isosorbide mononitrate is the relaxation of vascular smooth muscle, leading to vasodilation, or the widening of blood ...
  45. [45]
    Isosorbide mononitrate (oral route) - Side effects & dosage
    Aug 31, 2025 · Isosorbide mononitrate is used to prevent angina (chest pain) caused by coronary artery disease (heart disease).Missing: chemical compound
  46. [46]
    [PDF] Isordil Titradose (isosorbide dinitrate) Tablets - accessdata.fda.gov
    Controlled trials of single oral doses of isosorbide dinitrate have demonstrated effective reductions in exercise-related angina for up to 8 hours. Anti-anginal ...
  47. [47]
    Isosorbide Dinitrate Dosage Guide + Max Dose, Adjustments
    Jul 17, 2025 · Initial dose: 5 to 20 mg orally 2 or 3 times a day. Maintenance dose: 10 to 40 mg orally 2 or 3 times a day.
  48. [48]
  49. [49]
    Antianginal Efficacy of Oral Therapy with Isosorbide Dinitrate Capsules
    Isosorbide dinitrate administered in this fashion resulted in a significant reduction in anginal episodes, as compared with placebo. As compared to control, ten ...<|separator|>
  50. [50]
    Vasodilator Therapy: Nitrates and Nicorandil - PMC - PubMed Central
    The authors concluded that, overall, nitrate therapy reduced the number of angina episodes ... isosorbide dinitrate for nitrate tolerance in stable angina ...
  51. [51]
    Nitrates for stable angina: A systematic review and meta-analysis of ...
    Long-term administration of nitrates was beneficial for angina prophylaxis and improved exercise performance but might be ineffective for improving quality of ...
  52. [52]
    Nitrate tolerance - PubMed
    These studies have shown the following: Tolerance to the hemodynamic and antianginal effects of isosorbide dinitrate. Tolerance develops quickly and can be ...
  53. [53]
    Nitrate tolerance: influence of isosorbide dinitrate on the ... - JACC
    This study demonstrates that 1) tolerance to the hemodynamic and antianginal effects of isosorbide dinitrate develops rapidly, 2) nitroglycerin does not ...
  54. [54]
    Nitrate tolerance - PubMed
    Nitrate tolerance may be defined as that condition in which increasing nitrate doses are required to induce a given hemodynamic or antianginal effect.
  55. [55]
    Isosorbide - an overview | ScienceDirect Topics
    Osmotic Diuretics​​ The recommended initial dose of isosorbide is 1.5 gm per kg body weight. The onset of action is usually within 30 minutes, and the maximum ...
  56. [56]
    Experimental Use of Isosorbide: an Oral Osmotic Agent to Lower ...
    "Experimental Use of Isosorbide: an Oral Osmotic Agent to Lower Cerebrospinal Pressure and Reduce Brain Bulk" published on Aug 1966 by Journal of ...Missing: introduction 1960s
  57. [57]
    Isosorbide: An Oral Hyperosmotic Agent | JAMA Ophthalmology
    Isosorbide is an effective hyperosmotic agent which can be administered orally without gastrointestinal irritation. It is absorbed quantitatively and more.
  58. [58]
    Effect of penetration modifiers on the dermal and transdermal ...
    The study found that 10% DMI and DGME did not significantly enhance skin permeation of the tested active ingredients.<|separator|>
  59. [59]
    Incorporation of an Isohexide Subunit Improves the Drug-like ... - NIH
    Thus, there is a stereoelectronic preference for E2 elimination of an isosorbide exo leaving group at C-6 vs an endo leaving group at C-3. The site-selective ...
  60. [60]
  61. [61]
    Mononitrates: defining the ideal long-acting nitrate - PubMed
    Three different mononitrate formulations are available in the United States: Ismo tablets in December 1992; followed over a year later by Monoket tablets, ...Missing: non- applications
  62. [62]
    Effects and pharmacokinetics of isosorbide dinitrate in normal man
    ISDN was rapidly absorbed and metabolized, having an elimination half-life of 29 min. Its metabolites 2-ISMN and 5-ISMN had longer half-lives of 1.75 and 7.6 h ...
  63. [63]
    Pharmacokinetics and Safety with Bioequivalence of Isosorbide ...
    Jul 14, 2025 · Conclusion: The isosorbide mononitrate sustained-release tablet demonstrated bioequivalence to the reference formulation (Ismo® retard) under ...
  64. [64]
    Explaining the Phenomenon of Nitrate Tolerance
    Sep 30, 2005 · [Actions of pentaerithritol tetranitrate, isosorbide mononitrate and placebo on headache and ability to work of healthy subjects].
  65. [65]
    Nitrates - StatPearls - NCBI Bookshelf - NIH
    Jul 10, 2023 · Nitrate tolerance is a significant problem regarding chronic nitrate use. [3] Tolerance may develop quickly within 12 to 24 hours, and nitrates ...
  66. [66]
    Amelioration of nitrate tolerance: matching strategies with mechanisms
    Potential Mechanism(s) of Action ... Preserved endothelial function after long-term eccentric isosorbide mononitrate despite moderate nitrate tolerance.
  67. [67]
    Nitrates for stable angina: A systematic review and meta-analysis of ...
    Jan 7, 2011 · Chrysant et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris ... chronic stable angina ...
  68. [68]
    Isosorbide Mononitrate in Heart Failure with Preserved Ejection ...
    Nov 8, 2015 · In early studies in patients with heart failure with a reduced ejection fraction, long-acting nitrates improved activity tolerance, as assessed ...<|control11|><|separator|>
  69. [69]
    Isosorbide dinitrate inhibits platelet adhesion and aggregation ... - NIH
    Nonselected patients with acute myocardial infarction (AMI) have been suggested to gain no benefit from administration of nitrates. However, the importance of ...
  70. [70]
    Is isosorbide (isosorbide dinitrate) effective for treating acute ...
    Jul 7, 2025 · The drug label does not recommend the use of oral isosorbide dinitrate in acute myocardial infarction or congestive heart failure due to the ...
  71. [71]
    Full article: The future of isosorbide as a fundamental constituent for ...
    Aug 24, 2021 · Isosorbide possesses a stereochemistry and geometry suitable for making cost-effective chemicals, and a molecular rigid configuration ...
  72. [72]
    Degradable high Tg sugar-derived polycarbonates from isosorbide ...
    Polycarbonates from isosorbide and dihydroxyacetone (DHA) have been synthesised using organocatalytic step-growth polymerization of their corresponding diols ...<|separator|>
  73. [73]
    Next-generation polymers: Isosorbide as a renewable alternative
    Isosorbide has already proven to be a valuable renewable feedstock for a variety of polymers and applications, with further growth anticipated.
  74. [74]
    Transesterification of Isosorbide with Dimethyl Carbonate Catalyzed ...
    Jan 8, 2019 · Green synthesis of high-molecular-weight isosorbide-based polycarbonate (PIC) with excellent properties is a tremendous challenge and is ...
  75. [75]
    [PDF] N°6 september 2014 - Substitution
    According to its manufacturer, BISNEINEX is, by nature (it is a PET), approved in Europe and the United States for use in contact with food. This PET is ...
  76. [76]
    [PDF] B COMMISSION REGULATION (EU) No 10/2011 of 14 January ...
    Aug 31, 2023 · (12) 'food simulant' means a test medium imitating food; in its behaviour the food simulant mimics migration from food contact materials ...Missing: approval | Show results with:approval
  77. [77]
    Toxicology and Biodegradability of a Phthalate‐Free and Bio‐Based ...
    Jul 12, 2021 · The tests were performed according to OECD Guideline for Testing of Chemicals No. 301 [43]. The POLYSORB® ID 37 has been incorporated directly ...
  78. [78]
    Balancing the transesterification reactivity of isosorbide with ...
    These findings help to clarify the mechanism of ISB transesterification and provide new strategies for the synthesis of high-molecular-weight ISB-PCs. Graphical ...
  79. [79]
    Dimethyl Isosorbide As a Green Solvent for Sustainable ...
    Nov 25, 2019 · Dimethyl isosorbide (DMI)—a well-known biobased high boiling green solvent—was used for the first time in the preparation of poly(vinylidene ...
  80. [80]
    Isosorbide Market Size, Trends Report, Growth | Industry Analysis ...
    Jul 9, 2025 · The Isosorbide Market is expected to reach USD 0.69 billion in 2025 and grow at a CAGR of 8.03% to reach USD 1.02 billion by 2030.<|separator|>
  81. [81]
    Isosorbide, a green plasticizer for thermoplastic starch that does not ...
    Mar 30, 2015 · Isosorbide is an innovative renewable solid plasticizer for thermoplastic starch. •. Crystallinity and mechanical properties do not change in ...
  82. [82]
    Isosorbide: a sustainable, high-performance coating feedstock.
    Substituting isosorbide for existing petrochemical ingredients not only lightens the environmental impact of industrial polymers, it also drives up performance.
  83. [83]
    Epoxidized isosorbide-based esters with long alkyl chains as ...
    Our previous studies show that epoxidized cardanol esters with long alkyl side chains can be used as secondary plasticizers with good plasticizing performance ...
  84. [84]
    Nitrate Therapy | Circulation - American Heart Association Journals
    May 17, 2011 · In summary, nitrate tolerance (or rather GTN, ISMN, and ISDN tolerance) is a complex phenomenon caused by abnormalities in the biotransformation ...
  85. [85]
    Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the ...
    Jul 6, 2010 · Because both PDE5Is and nitrates increase cGMP, coadministration can generate excess accumulation of cGMP and can trigger marked vasodilation ...
  86. [86]
    Time course of the interaction between tadalafil and nitrates - PubMed
    Background: The PDE5 inhibitors augment the blood pressure (BP)-lowering effects of nitrates, yet the time course of this interaction is unclear. Recent ...
  87. [87]
    Isosorbide mononitrate Disease Interactions - Drugs.com
    Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.
  88. [88]
    Who can and cannot take isosorbide mononitrate and ... - NHS
    an underactive thyroid (hypothyroidism) · low blood pressure (hypotension); anaemia; glaucoma. More in Isosorbide mononitrate and isosorbide dinitrate.
  89. [89]
    Pharmacokinetics and Safety with Bioequivalence of Isosorbide ...
    Jul 14, 2025 · The study demonstrated isosorbide mononitrate sustained-release tablets (40 mg/tablet) were bioequivalent to branded formulation (40 mg/tablet) ...
  90. [90]
    Exploring the Growing Isosorbide Market: Advantages, Applications ...
    Apr 4, 2023 · Biodegradability: Isosorbide is readily biodegradable and does not accumulate in the environment, making it eco-friendlier than conventional ...
  91. [91]
    Isosorbide diester: bio-based, biodegradable plasticizers - Roquette
    ROQUETTE provides a sustainable plasticizer, POLYSORB® ID46 which is a bio-based isosorbide diester, a safe alternative to phthalates.
  92. [92]
    Biodegradability of novel high Tg poly(isosorbide-co-1,6-hexanediol ...
    Apr 1, 2022 · The biodegradation rate of isosorbide in pre-exposed soil increased immediately from 0.5 to 2.4 mg CO2 day−1 within 4 days. This indicates that ...
  93. [93]
    Biodegradability of renewable isosorbide and sebacate-based ...
    At 30 mol% isosorbide, the degradation extent reached 97.2 and 68.3 % after eight-week degradation in soil and 32-week degradation in a marine environment, ...
  94. [94]
    Relationship between Composition and Environmental Degradation ...
    Jan 26, 2024 · Even though CHDM was registered as readily biodegradable (OECD 301), (32) we did not observe biodegradation of CHDM (2.2 mg C g–1 dry soil) ...
  95. [95]
    Ecotoxicity of isosorbide acrylate and methacrylate monomers and ...
    Feb 1, 2023 · Isosorbide acrylate monomers are toxic to higher organisms, moderately toxic to bacteria. Methacrylate monomers are harmless. Polymers are ...
  96. [96]
    [PDF] Environmental Risk Assessment Data Isosorbide-5-mononitrate
    Oct 2, 2023 · No information on the potential for biodegradation or the environmental fate of isosorbide-5- mononitrate is available, therefore in the ...Missing: impact | Show results with:impact